Artivion (AORT) AI Stock Analysis

• Market Cap: $2.05B
• Dividend Yield: N/A
• Average Volume (3M): 541.26K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.07
• Revenue Growth: 7.44%
• EPS Growth: -109.83%
• Country: US
• Employees: 1,600
• Sector: Healthcare
• Sector Strength: 53
• Industry: Medical - Devices
• EPS (TTM): 0.03
• Shares Outstanding: 47,183,660
• 10 Day Avg. Volume: 400,416
• 30 Day Avg. Volume: 541,260
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: 4.00
• Enterprise Value/Gross Profit: 6.26
• Enterprise Value/Ebitda: 40.73
• 1Y Price Target: $42.40
• Price Target Upside: 3.31% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7

• Rating: 55 Neutral
• Price Target: $45.00 ▲(9.65% Upside)

Artivion's overall score is driven by strong earnings call results and positive corporate events, but is weighed down by financial performance challenges and lack of technical analysis data.

Positive Factors

Revenue Growth

Strong revenue and EBITDA growth indicate robust demand for Artivion's products, supporting long-term business expansion and market presence.

Financial Flexibility

Reducing debt through convertible notes exchange enhances financial flexibility, allowing Artivion to invest in growth opportunities and innovation.

Product Portfolio Expansion

Successful product launches like AMDS expand Artivion's market reach and strengthen its competitive position in the cardiovascular device sector.

Negative Factors

Profitability Challenges

Ongoing profitability issues, as indicated by negative net profit margins, may hinder Artivion's ability to reinvest in growth and sustain operations.

Cash Flow Concerns

Negative free cash flow indicates potential liquidity issues, limiting Artivion's capacity to fund new projects and handle unexpected expenses.

Operational Inefficiencies

Low conversion of income into cash flow suggests operational inefficiencies, which could affect Artivion's long-term financial health and growth prospects.

Artivion Business Overview & Revenue Model

Company Description

Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita Open Plus and E-vita Open Neo. It also provides E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. The company was founded in 1984 and is headquartered in Kennesaw, Georgia.

How the Company Makes Money

Artivion generates revenue primarily through the sale of its medical devices and surgical products. Key revenue streams include direct sales of its heart valves and associated surgical products to hospitals, surgical centers, and healthcare providers. Additionally, the company may derive income from licensing agreements, collaborations, and partnerships with other medical institutions and industry players. Significant factors contributing to its earnings include the growing demand for minimally invasive surgical solutions, advancements in cardiovascular treatments, and the company's ongoing investment in research and development to expand its product portfolio.

Artivion Financial Statement Overview

Summary

Artivion shows modest revenue growth but struggles with profitability and cash flow challenges. The reduction in leverage is positive, but operational inefficiencies need addressing.

Income Statement

Artivion's income statement shows a modest revenue growth rate of 3.83% TTM, indicating a slow but positive growth trajectory. However, the company is struggling with profitability, as evidenced by a negative net profit margin of -4.43% TTM. The gross profit margin remains healthy at 63.99%, but the EBIT and EBITDA margins have declined compared to previous periods, reflecting operational challenges.

Balance Sheet

The balance sheet highlights a significant improvement in the debt-to-equity ratio, which decreased to 0.02 TTM from over 1.3 in the previous year, suggesting a reduction in leverage. However, the return on equity remains negative at -5.54%, indicating ongoing profitability issues. The equity ratio is stable, reflecting a balanced asset structure.

Cash Flow

Cash flow analysis reveals a concerning trend with negative free cash flow and a high free cash flow to net income ratio of -5.59 TTM, indicating cash flow challenges. The operating cash flow to net income ratio is low at 0.03, suggesting inefficiencies in converting income into cash flow. Despite a significant free cash flow growth rate, the overall cash flow position remains weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	405.04M	388.54M	354.00M	313.79M	298.84M	253.23M
Gross Profit	259.20M	248.78M	229.18M	202.52M	197.51M	167.78M
EBITDA	39.81M	50.97M	26.87M	25.30M	25.67M	27.68M
Net Income	-17.93M	-13.36M	-30.69M	-19.19M	-14.83M	-16.68M
Balance Sheet
Total Assets	838.39M	789.10M	792.40M	762.80M	793.05M	789.40M
Cash, Cash Equivalents and Short-Term Investments	53.48M	53.46M	58.94M	39.35M	55.01M	61.41M
Total Debt	8.79M	362.26M	358.34M	356.83M	362.04M	317.37M
Total Liabilities	418.49M	512.90M	510.62M	478.47M	492.32M	460.69M
Stockholders Equity	419.90M	276.20M	281.78M	284.33M	300.73M	328.71M
Cash Flow
Free Cash Flow	-11.08M	11.05M	11.39M	-15.87M	-15.68M	5.04M
Operating Cash Flow	1.98M	22.24M	18.82M	-5.15M	-2.58M	12.37M
Investing Cash Flow	-28.99M	-28.19M	-502.00K	-10.71M	5.66M	-73.13M
Financing Cash Flow	8.18M	2.20M	865.00K	-1.64M	-12.22M	93.61M

Artivion Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 41.04
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AORT, the sentiment is Neutral. The current price of 41.04 is below the 20-day moving average (MA) of 43.30, above the 50-day MA of 36.78, and above the 200-day MA of 29.96, indicating a neutral trend. The MACD of 1.64 indicates Positive momentum. The RSI at 50.14 is Neutral, neither overbought nor oversold. The STOCH value of 24.47 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for AORT.

Artivion Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AXGN	69 Neutral	$739.42M	―	-4.48%	―	17.17%	72.68%
AORT	55 Neutral	$2.05B	―	-5.01%	―	7.44%	-109.83%
OFIX	54 Neutral	$580.57M	―	-24.63%	―	4.84%	0.85%
BVS	53 Neutral	$578.75M	―	-0.10%	―	5.08%	99.38%
KIDS	52 Neutral	$483.67M	―	-11.49%	―	26.08%	-63.67%
Sector *	51 Neutral	$7.90B	-0.36	-43.38%	2.23%	22.34%	-2.15%
TNDM	49 Neutral	$835.83M	―	-111.91%	―	25.84%	-47.67%

Artivion Corporate Events

Artivion Appoints Lance A. Berry as COO

On August 6, 2025, Artivion, Inc. announced the appointment of Lance A. Berry as Chief Operating Officer, effective August 11, 2025. Berry, who will continue his roles as Chief Financial Officer and Treasurer, brings extensive experience from his previous positions at Wright Medical Group N.V. and Arthur Andersen. His compensation package includes a base salary, cash incentives, and equity grants. Additionally, Marshall S. Stanton, Senior Vice President, Clinical Research and Chief Medical Officer, announced his retirement effective March 31, 2026. Stanton will continue to offer strategic advice and transition services for up to a year post-retirement.

The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.

Artivion Completes Convertible Notes Exchange Agreement

On May 28, 2025, Artivion, Inc. announced the completion of transactions related to privately negotiated exchange agreements with holders of its 4.250% Convertible Senior Notes due 2025. These transactions involved exchanging approximately $99.54 million in principal amount of notes for 4,334,347 shares of common stock and a cash payment of $1.7 million for accrued interest. This move effectively retires the convertible notes, significantly reducing the company’s debt and enhancing its financial flexibility, as stated by CEO Pat Mackin.

The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.

Artivion Shareholders Approve Directors and Compensation

At the 2025 Annual Meeting of Stockholders on May 13, Artivion‘s shareholders elected all nominated directors and approved executive compensation packages. Additionally, they ratified Ernst & Young LLP as the independent auditor for 2025 and approved additional shares for the company’s equity incentive plan, indicating strong shareholder support for the company’s strategic direction.

The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.

Artivion Announces Convertible Notes Exchange Agreement

On May 14, 2025, Artivion, Inc. announced that it entered into privately negotiated exchange agreements with holders of its 4.250% Convertible Senior Notes due July 1, 2025. The agreements involve exchanging approximately $94.54 million in principal amount of these notes for shares of the company’s common stock, with the number of shares determined by the stock’s average trading price over a specified period. The transaction is expected to close around May 28, 2025, and will leave approximately $5.46 million of the notes outstanding. This strategic move is anticipated to impact Artivion’s financial structure and market positioning, potentially affecting stakeholders by altering the company’s debt and equity composition.

The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.